Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Shire Profit Plunges On Impairments; Stock Down - Update

Dublin-based drug maker Shire plc (SHPG,SHP.L), Thursday reported a plunge in fourth-quarter profit, hurt by impairment charges related to its chronic constipation drug Resolor, as well as litigation charges. Shire stock lost 7 percent in afternoon trade on the Nasdaq, and ended 5 percent lower in London.

Revenues for the quarter increased from the prior year and were in line with Street expectations. Revenues rose on growth of Vyvanse and Intuniv indicated in the treatment of attention-deficit hyperactivity disorder (ADHD), as well as on Hunter Syndrome drug Elaprase, and gastrointestinal drug Lialda/Mezavant.

Sales of erstwhile key ADHD drug Adderall XR drug slipped, hurt mainly by generic competition. A new competition for the drug emerged, as earlier today, Teva Pharmaceutical Industries Ltd. (TEVA), the world's biggest maker of generic medicines, said it won approval from the U.S. Food and Drug Administration for a version of Adderall XR.

Shire meanwhile said it believes that branded Adderall XR can continue to compete successfully in a generic market. However, the company warned royalties and other revenues for 2013 are expected to be 30 to 40 percent lower, due mainly to the impact of the lower Adderall XR authorized generic royalty rate receivable from Impax, along with generic rivalry and patent expiry on other products.

Shire reported fourth-quarter net income of $42 million or 22.2 cents per American Depositary Share, or ADS. This compares with net income of $255 million of 133.2 cents per ADS last year.

Results for the quarter include impairment charges of $205 million, including $126.7 million charges of intellectual property rights acquired for Resolor in the EU. Other items included litigation charges of $49 million.

Excluding items, adjusted earnings for the quarter were 157.8 cents per ADS, compared with 151.2 cents per ADS a year ago.

On average, 10 analysts polled by Thomson Reuters expected earnings of $1.58 ADS for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter totaled $1.20 billion, compared with $1.14 billion in the prior year. Analysts on consensus estimated revenues of $1.20 billion for the quarter.

Sales of Adderall XR slid 35 percent to $82 million, while Vyvanse gained 18 percent to $256.5 million. Sales of ADHD drug Intuniv rose 24 percent to $81 million.

The company expects financial results to show further growth in line with current consensus earnings expectations for 2013, based on the estimates compiled by Consensus Forecast Ltd. of $6.72 non-GAAP earnings per ADS for fiscal year 2013.

Shire is trading at $93.62, down 6.73%, on a volume of 0.6 million shares. In London, the stock closed at 2,027.00 pence, down 5.50%, on a volume of 4.7 million shares.

Register
To receive FREE breaking news email alerts for Shire plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.